Marking an important milestone in the development of new cancer treatments the University of Kansas Cancer Center is opening a Phase I clinical trial using Nanotax, a new ovarian cancer drug developed by KU researchers.
Aired August 24, 2008
2 minutes (3.7 MB) | Download mp3
A new clinical trial could offer fresh options for ovarian cancer patients. From the University of Kansas, this is Research Matters. I'm Brendan Lynch.
Federal regulators recently approved a Phase I clinical trial for Nanotax, an ovarian cancer drug developed by KU researchers. The trial begins soon for select patients at the KU cancer center, which is headed by Dr. Roy Jensen.
Jensen: "Nanotax was discovered developed and will be delivered at clinical trails right here at KU. This is referred to as bench-to-bedside research. I would add that this trail is only the beginning, because our goal is to be the number-one academic producer of anti cancer drugs."
Nanotax is a reformulation of Paclitaxel, a drug delivered in a solvent associated with unpleasant side effects. For ovarian cancer survivors like Deatta Lackey, Nanotax could mean more tolerable treatments than those currently offered.
Lackey: I had a total of 12 chemo treatments. I had my treatments on Thursday, I would go to work on Friday, and then Saturday and Sunday is when I experienced extreme fatigue, body aches, nausea, mouth sores and low white blood count. At one point during the treatment, I had to give myself shots in my abdomen. I think any research for new treatments is important because I don't ever want to see anyone go through what I had to go through.
If approved, CritiTech, a pharmaceutical firm spun off from KU, would market the drug cancer patients. Sam Campbell leads CritiTech.
Campbell: "This is our combined ultimate goal, to save lives and ensure patients have access to promising cancer fighting drugs. Nanotax is a perfect example of the potential that lies before us in this region. The heartland is home to a wealth of resources in the biosciences that, by working together, have the opportunity to genuinely improve outcomes for patients.
For more on Nanotax, log onto Research Matters dot KU dot edu. For the University of Kansas, I'm Brendan Lynch.
Tell Me More
University of Kansas Cancer Center opens innovative Phase I clinical trial
KANSAS CITY, Kan. - Marking an important milestone in the development of new cancer treatments, officials from the University of Kansas Cancer Center announced the opening of a Phase I clinical trial using a new ovarian cancer drug developed by KU researchers.